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ABSTRACT 
 
Mitochondrial disorders constitute a subgroup of the large family of rare monogenic diseases 
called Inborn Errors of Metabolism (IEM), but defects in mitochondrial activity have also 
been reported in more common and complex pathologies.  
In the present thesis, I validate new disease-causing variants and study the underlying 
molecular defects in three different cases of IEM. 
 
In paper I, I report the first individuals suffering from slowly-progressive, early-onset 
neurodegeneration caused by loss-of-function mutations in the autophagy adaptor 
Sequestosome 1 (SQSTM1, or p62). Analysis of fibroblasts from these patients suggests a 
defect in the early response to mitochondrial stress and in autophagosome formation. 
 
In paper II, I further investigate the phenotype of two of the previously reported patients, 
using reprogrammed neuroepithelial stem (NES) cells and differentiated neurones. Loss of 
p62 in NES cells leads to an impairment in neuronal differentiation, possibly due to an 
inability to switch between glycolytic and oxidative metabolism.  
 
In paper III, I study the consequences of the lack of Thioredoxin interacting protein (TXNIP) 
in myoblasts and fibroblasts of affected individuals. Oxygen consumption measurements 
revealed decreased mitochondrial activity, depending on the supplied carbon source. In 
particular, patient cells are unable to utilise the end product of glycolysis - pyruvate - but can 
efficiently use the tricarboxylic acid (TCA) cycle intermediate, malate, to fuel mitochondrial 
energy production. This expands the current view of the role of TXNIP in physiology and 
pathology. 
In paper IV, I model a neurodegenerative disorder related to mutations in the mitochondrial 
tryptophanyl-tRNA synthetase (WARS2) gene, after assessing pathogenicity of the variants in 
yeast. Knock down of WARS2 in Drosophila melanogaster resulted in larval lethality and 
reduced aminoacylation of tRNATrp, much resembling what can be observed in the affected 
individuals. Although muscle biopsies and fibroblasts from patients did not reveal a 
mitochondrial dysfunction, reprogrammed NES cells displayed a combined Complex I and IV 
defect, strengthening the relevant tissue-specificity of mitochondrial disorders. Our results 
demonstrate the importance of using appropriate models for the characterisation of mutations 
and for the efficient validation of pathogenic variants. 
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1. INTRODUCTION 
1.1 Introduction to metabolism 
  
“For things to remain the same, everything must change”: what is written in the 1958 novel 
by Giuseppe Tomasi di Lampedusa “The Leopard” can easily be seen as a general rule of 
Nature. Balancing continuous changes is what maintains life as we know it, and for this 
reason every organism struggles towards homeostasis. The repertoire of choices at the 
disposal of living beings to efficiently keep an equilibrium, while constantly modifying 
themselves, is metabolism. The word “metabolism” stems from Greek µεταβολή, “change” 
and was first used in 1839 by Schwann (Schwann 1839), before being adopted into English 
(Bing 1971). Yet, the concept of metabolism originates earlier, in 1836, when Tiedemann 
introduced the notion of Stoffwechsel, i.e. “the conversion of body substance into other forms 
and the rapid production of new and precisely similar body structures by means of the 
constant supplying of nourishing material” (Tiedemann 1836). With the years, the word 
“metabolism” has acquired the more specific meaning of a complicated network of 
biochemical and enzymatical reactions that sustains living organisms (Fig. 1).  
 
 
 
 
 
Fig.1: schematic outline of the main pathways constituting the metabolic network.   
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Metabolic reactions can be divided into two major groups, depending on whether they are 
constructive or destructive: anabolic reactions promote the conversion of simple molecules 
into more complex ones, normally consuming energy, while catabolic reactions promote the 
breakdown of complex molecules into simple ones, and release energy. To coordinate this 
tangled system, each cell needs to finely tune its needs and regulate different pathways in an 
independent way; naturally, various compartments will have varying demands at different 
timepoints and thus communication within cellular environments cannot be underestimated.  
 
1.2 Introduction to metabolic disorders 
 
Under the broad class of “Inborn Errors of Metabolism” (IEM), a term coined by Sir 
Archibald Garrod in 1923, a group of pathological situations affecting around 1:1000 
newborns is represented. These diseases are defined by a loss or toxic accumulation of 
metabolic intermediates, and normally emerge at a neonatal stage. Disease progression is 
usually rapid, although age of onset can vary from birth to adulthood (El-Hattab 2015). 
Mitochondrial dysfunctions form the largest subgroup within IEM, and are classically 
defined as deficiencies in oxidative phosphorylation (OXPHOS), leading to impaired ATP 
synthesis and, ultimately, to insufficient energy production. The clinical spectrum of the 
affected patients can vary greatly, but often includes myopathy, ataxia, vertical gaze palsy 
and, if any involvement of the central nervous system is present, a cerebellar syndrome.  
 
Recent years have witnessed an explosion of investigations suggesting a critical role of 
mitochondria in more common disorders (Murphy and Hartley 2018), e.g. heart disease 
(Schwarz et al. 2014), diabetes (Karaa and Goldstein 2015), cancer (Porporato et al. 2018) 
and neurodegeneration (Martin 2012; Burté et al. 2015). Yet, the mitochondrial role in 
widespread pathophysiological conditions represents a main issue to be elucidated and the 
next challenge for future research (Nunnari and Suomalainen 2012; Vafai and Mootha 2012).  
The field of neurodegeneration has shown a particular interest in mitochondria. More and 
more studies are hinting at the essential function these organelles have for neuronal well-
being (Kann and Kovács 2007; Mattson et al. 2008); not only because they are at the core of 
cellular metabolism, but also for their fundamental role in keeping production of Reactive 
Oxygen Species (ROS) in efficient balance. For example, reduced activity of Complex I is 
one of the landmarks of Parkinson’s (Bose and Beal 2016; Park et al. 2018) and deletions in 
mitochondrial DNA (mtDNA) might contribute to Alzheimer’s disease (Phillips et al. 2014). 
Furthermore, dysfunctional organelles and their accumulation have also been described in 
amyotrophic lateral sclerosis (ALS) (Martin 2011; Muyderman and Chen 2014; Khalil and 
Liévens 2017). The possibility that mitochondrial malfunctioning can affect neuronal health 
should not be surprising, taken into consideration the importance of energy production for 
our central nervous system. In fact, it is there that we require and consume most of the 
glucose that is taken in every day. Oxygen pressure and the access to it by the brain are of 
extreme importance; in fact, too low or too high concentrations can both cause cell damage 
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and ultimately death. Furthermore, the post-mitotic status of neurones impedes any 
replacement of faulted cells with new ones, making it impossible to fully reconstitute their 
original pool. 
 
1.3 Introduction to mitochondria 
 
When Altmann first described mitochondria in 1890, he baptised them “bioblasts”. Only 
eight years later, in 1898, microbiologist Carl Benda named them from the Greek µίτος, 
“thread” and χονδρίον, “granule” (Ernster and Schatz 1981).  These organelles evolved from 
an alphaproteobacterium that started an endosymbiotic relationship with a prokaryotic cell. 
Even though the exact timing and mechanism of the onset of this relationship are matter of 
vivid debate (Roger et al. 2017), what is considered established is the inheritance 
mitochondria still retain of their past: in fact, they maintain a prokaryotic genome, a circular 
16.5 kb DNA molecule containing 37 genes, among which 13 polypeptides, 22 tRNAs and 
2 rRNAs, all essential for correct function of the organelles (Falkenberg et al. 2007; 
Gustafsson et al. 2016). These gene products are necessary but not sufficient for proper 
mitochondrial function. Besides the mtDNA-derived peptides over 1000 mitochondrial 
proteins are encoded in the nuclear genome and need to be imported into mitochondria 
(Schmidt et al. 2010; Wiedemann and Pfanner 2017). Mitochondria are thus under dual 
genetic control, requiring careful coordination. 
 
Mitochondria are enclosed by an outer membrane, and their internal space is portioned into 
a matrix and an invaginated inner membrane, thus increasing the surface to volume ratio and 
optimising the space at disposal. As mentioned before, they constitute the central hub of 
cellular metabolism, as they are involved in numerous vital functions, such as steroid 
synthesis, initiation of apoptosis, Ca2+ and ROS signaling, as well as the final steps of aerobic 
energy metabolism. In their matrix, oxidation of acetyl-CoA during the TCA cycle leads to 
the reduction of flavin adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide 
(NAD+) to FADH2 and NADH, respectively. A number of metabolic pathways converge to 
the TCA cycle, including glycolysis and beta-oxidation of fatty acids, that supply acetyl-
CoA, or protein catabolism, that can provide the cycle with intermediates. 
Reduced FADH2 and NADH are then used in OXPHOS, a broad term that designates the 
coupling of an electron transport chain (ETC) with ATP production across the inner 
mitochondrial membrane. The hypothesis that the reducing power released by the ETC is 
not freed in the mitochondrial or cellular environment, but is, instead, efficiently used, was 
first conceived by Herman Kalckar in 1939. He demonstrated a correlation between the 
transport of electrons in mitochondria and ATP production (Kalckar 1939), but the exact 
mechanism by which this coupling can be accomplished remained for some years 
mysterious, until in 1961 Peter Mitchell formulated his now renowned chemiosmotic theory 
(Mitchell 2011). In this model, the ETC transfers electrons from reduced NADH and FADH2 
to molecular oxygen via a series of redox reactions (Krebs and Johnson 1937), while at the 
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same time generating an electrochemical proton gradient across the inner mitochondrial 
membrane. This gradient is then used as a driving force by an ATP synthase (Complex V) 
to synthesise ATP from ADP and phosphate.  
 
Four complexes, sitting on the cristae in the inner membrane, compose the ETC, aided in 
their work by the two electrons-carriers ubiquinone (UQ, also known as Coenzyme Q, or 
CoQ10) and Cytochrome c (CytC) in the intermembrane space (Fig. 2): 
Complex I (NADH dehydrogenase or NADH:ubiquinone oxidoreductase), consecutively 
transfers two electrons from NADH to a molecule of Coenzyme Q, thereby reducing 
ubiquinone to ubiquinol. It is the largest complex, consisting of 45 subunits, with seven 
encoded by mtDNA. The catalytic core of the complex constitutes 14 subunits, with an 
additional 31 subunits in mammals. Recently, the full structure was resolved by Zhu, 
Vinothkumar and Hirst, revealing the exact electron flow through the complex (Zhu et al. 
2016). However, how the redox reaction of NADH to ubiquinol is coupled to proton pump 
remains to be solved. 
Complex II (Succinate dehydrogenase or Succinate:ubiquinone oxidoreductase) is also a 
member of the TCA cycle and therefore sits on the matrix side. It oxidises succinate to 
fumarate, at the same time reducing the covalently bound FAD to FADH2, which is in turn 
used to fuel sequential reduction of ubiquinone into ubiquinol. Unlike Complex I, the 
reduction of ubiquinone is not coupled to proton translocation across the inner mitochondrial 
membrane. Additionally, it is the only complex of OXPHOS with all of its four subunits 
being encoded in the nuclear genome. 
Complex III (Cytochrome c reductase or Ubiquinol:cytochrome c reductase) oxidises 
ubiquinol into ubiquinone, while reducing CytC, freeing the coenzyme to accommodate new 
electrons from Complexes I and II. It consists of 11 subunits, one encoded in mtDNA and 
the rest in the nuclear genome.   
Complex IV (Cytochrome c oxidase or ferrocytochrome c:oxygen oxidoreductase) oxidises 
reduced CytC and passes electrons on to molecular oxygen, finally producing water. It 
consists of 20 subunits, of which 3 are encoded by mtDNA. 
 
These four complexes constitute the mitochondrial ETC. By pumping protons across the 
inner mitochondrial membrane, Complexes I, III and IV promote formation of the proton 
motive force that is used by the ATP synthase. 
 
Complex V is also known as ATP synthase and works as a dynamo, synthesizing ATP from 
ADP and phosphate. In brief, the re-entry of protons to the mitochondrial matrix is coupled 
with rotation of its F0 subunit, which results in the physical condensation of ADP and 
phosphate in its F1 subunit. It is composed of 20 subunits of which two are encoded by 
mtDNA and the rest in the nuclear genome. The way these subunits are assembled and the 
final structure of the protein has been resolved over the years by the group of John Walker 
(see, e.g. (Watt et al. 2010)). 
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Fig.2: schematic overview of oxidative phosphorylation. CI: NADH dehydrogenase, CII: Succinate 
dehydrogenase, CIII: Cytochrome c reductase, CIV: Cytochrome c oxidase, CV: ATP synthase. Four protons 
are extruded in the intermembrane space at CI and CIII, two protons at CIV. Below each complex, the 
respective electron donor and receiver are listed. 
 
As most things in biology, mitochondria are not static entities; rather, they endure in 
continuous phenomena of fusion and fission, that respectively decrease or increase the 
number of organelles at a cell’s disposal. These events are tightly controlled and require a 
strict interplay between different cellular microenvironments and signalling pathways 
(Youle and van der Bliek 2012; Archer 2013). Furthermore, mitochondria are highly mobile 
and continuously travel across the cell to reach the areas where they are more needed. In this 
way, a cell has always the chance to spatiotemporally coordinate its energy demands and 
supply. 
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1.4 Introduction to ROS and oxidative stress response 
 
ROS constitute the byproduct of aerobic metabolism and include anion superoxide (O2•-), 
hydrogen peroxide (H2O2), and hydroxyl radicals (OH•). All these molecules exert a dual 
role: on one hand they are toxic and can interact with DNA, proteins and lipids promoting 
their damage, ultimately contributing to conditions as neurodegeneration and aging. On the 
other hand, they can be messengers, promoting communication between cellular 
compartments (Yoboue et al. 2018) and are important for the immune response (Yang et al. 
2013).  
 
The main origin of ROS is the ETC, where they are produced depending on the 
electrochemical proton potential across the inner mitochondrial membrane, the ratio between 
NADH/NAD+ and between reduced and oxidized ubiquinone. Understandably, also local O2 
concentration plays a role (Murphy 2009). Numerous studies have been conducted during 
the years to pinpoint the major source of ROS production.  
Complex I and Complex III have been identified as the components of the ETC where most 
of O2•-  is generated, even if contribution of the latter can have been overestimated (Adam-
Vizi and Chinopoulos 2006), as it seems to have a more important role in the production of 
hydrogen peroxide (Chen et al. 2003).  Both the flavin and the ubiquinone binding site of 
Complex I are involved in ROS formation (Pryde and Hirst 2011; Hirst and Roessler 2016), 
while in Complex III ROS seem to be produced at the ubiquinol oxidation centre (centre P, 
Qo site) (Bleier and Dröse 2013). 
In particular, impaired or reduced mitochondrial respiration leads to O2•- formation via an 
increase in the NADH/NAD+ ratio. Complex I can also produce large amounts of ROS when 
it operates in reverse, that is when a reduction in the UQ pool increases the proton motive 
force, favouring electron flux back through Complex I (Hinkle et al. 1967; Pryde and Hirst 
2011). Small contribution from other mitochondrial enzymes, such as 2-oxoglutarate 
dehydrogenase (a-ketoglutarate dehydrogenase, aKGDH) can also, under some conditions, 
influence mitochondrial ROS content (Murphy 2009). 
 
To counteract possible damages caused by ROS, cells and mitochondria have evolved 
efficient removal methods. In the mitochondrial matrix, manganese superoxide dismutase 
(MnSOD or SOD2) actively transforms potentially toxic O2•- into H2O2. 
H2O2 is then in turn degraded by the thioredoxin and the glutathione systems, two disulphide 
reductase mechanisms, both existing also in a cytosolic form and utilising the reducing 
power of the NADPH/NADP+ couple to efficiently eliminate the damaging molecules (Ren 
et al. 2017). The efficiency of this approach is what ultimately regulates the messenger 
capacity of ROS, so that proper signalling can take place (Collins et al. 2012).  Many cellular 
responses, such as oxygen sensing (Guzy et al. 2005), differentiation (Tormos et al. 2011; 
Zhou et al. 2016), and mitochondrial homeostasis (St-Pierre et al. 2006), are influenced by 
the presence of ROS and thus controlled.  
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1.5 Introduction to autophagy 
 
The process of autophagy consists of the removal of damaged or non-functional proteins and 
organelles.  
Autophagy can be classified into non-selective and cargo-specific autophagy. In the first 
case, nutrient deprivation promotes catabolism to supply the cell with building blocks. In the 
second case, autophagy is promoted even if there is no shortage of nutrients or energy to 
remove damaged organelles or potentially toxic protein aggregates.  
Alternatively, autophagy can be classified as either chaperone-mediated, micro-, or macro-
autophagy. In particular, macroautophagy involves the sequestration of cargo into double-
membraned vesicles, termed autophagosomes, whose formation is promoted by members of 
the autophagy-related genes (ATG) family (Mizushima et al. 2011), and which can fuse with 
lysosomes, where the low pH and different enzymes finally favour degradation of their faulty 
content.  
 
Because autophagy has a very important role for cellular well-being, different studies have 
tried to identify ways to efficiently promote or inhibit it. 
On the one hand, the antibiotic rapamycin can promote autophagy by forming a complex 
with the intracellular receptor FKBP12 and physically interact with the main autophagy 
inhibitory signal in the cell; the mammalian target of rapamycin complex 1 (mTORC1) 
(Dumont and Su 1996), a well-studied pathway involved in various cellular processes. On 
the other hand, the autophagic flux can be blocked by inhibitors of the lysosomal proton 
pump, such as bafilomycin and chloroquine (Levine and Kroemer 2008).  
 
Mitophagy is one example of cargo-specific autophagy that sustains elimination of 
mitochondria.  
It has been shown that this process has a fundamental role in maintaining the appropriate 
number of organelles and ensuring constant health of their network (Kim et al. 2007). The 
current mitophagic model (Fig.3) begins with the loss of the mitochondrial membrane 
potential, which impedes mitochondrial protein import, as well as degradation, of PTEN-
induced putative kinase protein 1 (PINK1), which eventually accumulates on the outer 
surface of the organelle. PINK1, in turn, recruits the E3-ubiquitin ligase Parkin that links 
polyubiquitin chains to various targets on the outer mitochondrial membrane, ultimately 
sending the depolarised organelles to lysosomal degradation. 
 This process is mediated via the microtubule associated protein 1 light chain 3 alpha (LC3), 
a protein responsible for the recruitment of the autophagosome (Youle and Narendra 2011). 
During autophagy, cytosolic LC3 (LC3-I) is conjugated to a molecule of 
phosphatidylethanolamine to obtain LC3-phosphatydilethanolamine conjugate (LC3-II) that 
can be recruited to autophagosomal membranes.  
Ubiquitinated mitochondria are recognised and bound by Sequestosome 1 (SQSTM1/p62), 
that interacts with activated LC3 to finally lead them to degradation (Park et al. 2014).  
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This paradigm has been supported by the scientific literature (Narendra et al. 2008); still, in 
recent years, the role of p62 in this process is a matter of vivid debate (Fon 2013; Strappazzon 
et al. 2015), and p62 is suggested to be only necessary for mitochondrial clustering and not 
for mitophagy per se (Narendra et al. 2010; Okatsu et al. 2010).  
Work presented in this thesis also investigated the role of p62 in mitophagy, proposing a 
different function during this process (Haack et al. 2016; Calvo-Garrido et al. 2019). 
 
 
 
 
Fig.3: schematic overview of the proposed mitophagic model.  
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1.6 Introduction to the projects 
 
In the present thesis, I focus my effort on the proteins briefly discussed below:  
 
1.6.1 SQSTM1/p62 
 
SQSTM1 is also known as p62 or as A170. It was first discovered in 1996 as ligand of p56lck 
and specifically binds its Src homology 2 (SH2) domain (Joung et al. 1996). Just a few 
months later, it was described as a member of a new class of ubiquitin-binding proteins. As 
the name suggests, it is a 62 kDa protein, composed of 440 amino acids, and it has various 
domains interacting with a number of different pathways. In particular, the N-terminal region 
seems to be important for dimerization, while the C-terminus is essential for binding of 
ubiquitin (Vadlamudi et al. 1996) (Fig.4).  
 
  
 
Fig.4: schematic overview of the structure of p62. The different domains are highlighted with different colours 
that also identify the corresponding interactors. PB1: Phox and Bem1. ZZ: Zinc finger. TB: TGFb-binding-
protein-like. LIR: LC-3 interacting region. KIR: Keap1 interacting region. UBA: Ubiquitin associated. aPKC: 
Protein kinase C. ERK: Extra-cellular signal regulated kinase. NBR1: Neighbour of BRCA1 gene 1. RIP: 
Receptor-interacting protein kinase. TRAF6: TNF-receptor associated factor 6. 
 
Over the years, numerous studies have highlighted the importance of p62 in different 
processes, as diverse as cell proliferation (Qiang et al. 2014) or the removal of the 
microtubule associated protein Tau (MAPT) (Xu et al. 2019). This is of particular 
importance in neurodegenerative disorders, as abnormal phosphorylation of MAPT is a 
hallmark of Alzheimer’s, and mutations in its gene have been correlated with Frontotemporal 
Dementia (FTD) (Iqbal et al. 2016).  
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p62 also plays a role in the oxidative stress response, via the antioxidant response elements 
(ARE) present in its promoter (Jain et al. 2010). Furthermore, the oxidation of two cysteine 
residues (Cys105/103) in p62 has been proposed to act as oxygen sensor (Carroll et al. 2018). 
Additionally, p62 is known to regulate Kelch-like ECH associated protein 1 (KEAP1) 
expression, promoting its degradation and making it unable to inhibit nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2). Stabilisation of Nrf2 leads to its translocation to the 
nucleus and promotes transcription of genes related to the oxidative stress response, such as 
NAD(P)H quinone oxidoreductase 1 (NQO1) or other components of the glutathione system 
(Komatsu et al. 2007; Copple et al. 2010; Fan et al. 2010; Lau et al. 2010; Kwon et al. 2012). 
Last but not least, via its ubiquitin-binding domain, p62 is thought to play a major role in 
autophagy (Dikic and Elazar 2018; Zaffagnini et al. 2018).  
 
Mutations in the last exons of p62 were causatively correlated to Paget’s disease of bones 
(Laurin et al. 2002), while others were related to frontotemporal lobar dementia (FTLD) 
(Arai et al. 2003) and ALS (Fecto et al. 2011). Moreover, p62 inclusions have been observed 
in post mortem tissues from individuals suffering from protein aggregation disorders 
(Zatloukal et al. 2002).  
 
In mice, knock out of p62 leads to adult onset obesity, leptin resistance and glucose 
intolerance (Rodriguez et al. 2006). Ramesh Babu and colleagues have also reported 
hyperphosphorylated MAPT and neurofibrillary tangles, clear signs of neurodegeneration, 
in mice deprived of p62, closely resembling what is observed in humans (Haack et al. 2016). 
Interestingly, the mice also developed behavioural symptoms and showed signs of increased 
anxiety, depression and working memory loss (Ramesh Babu et al. 2008) that were not 
reported in patients.  
 
As this demonstrates, it is very hard to pinpoint the exact mechanism by which decreased 
expression of a scaffold protein like p62 can impair cellular well-being and, ultimately, 
individual health, because of its considerable tissue specificity and multitude of interactions.  
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1.6.2 TXNIP 
 
The thioredoxin system is essential for ROS scavenging and cellular well-being. 
Thioredoxin-interacting protein (TXNIP), a member of the a-arrestin family, binds to, and 
inhibits, thioredoxin activity, thus regulating the response to oxidative stress and redox 
homeostasis (Nishiyama et al. 1999). Nevertheless, the role of TXNIP does not seem to be 
only directly related to ROS management and oxidative stress response. Numerous reports 
relate TXNIP to the suppression of Nrf2 activity (Cebula et al. 2015)  and to the activation 
of the NOD-like receptor Protein-3 (NLRP3) inflammasome (Abderrazak et al. 2015). 
Interestingly, Nrf2 and the inflammasome are also tightly connected via Nrf2 itself, which 
can inhibit TXNIP action, suggesting a complex relationship between their activities (Hou 
et al. 2018).  Apart from contributing to the expression of ARE, and thereby reducing the 
burden of oxidative stress, Nrf2 also directs glucose towards anabolic pathways. It has 
therefore been implicated as an important factor in the protection against diabetes (Uruno et 
al. 2015).  
Studies in HeLa cells suggest that TXNIP expression is regulated by the glycolytic flux, and, 
in turn, by mitochondrial aerobic metabolism. In particular, inhibition of the ETC and ATP 
synthase leads to decreased TXNIP levels at both mRNA and protein level (Yu et al. 2010). 
 
The downstream metabolic consequences, resulting from a loss of TXNIP, are rather well 
demonstrated by full-body knock out mice. Although TXNIP knock out mice are viable, they 
are unable to efficiently retain normoglycemia during fasting, and present with a failure to 
regulate the switch between an unfed and fed state (Chutkow et al. 2008). This is in line with 
observations made in humans, were TXNIP expression has been proposed to be antithetically 
regulated by insulin and glucose (Parikh et al. 2007). Furthermore, and more importantly for 
the scope of this thesis, TXNIP deletion in mice has shown functional and structural 
mitochondrial deficiency (Yoshioka et al. 2012).  
  
 12 
1.6.3 WARS2 
 
Aminoacyl-tRNA synthetases (aaRSs) are proteins involved in the formation of an ester 
bond between an aminoacid and its cognate tRNA. Two spatially separate pools exist, a 
cytoplasmic and a mitochondrial that can also be divided into two classes depending on their 
chemical properties. In mitochondria there are 19 aaRSs for the 23 mt-tRNAs, highlighting 
some redundancy.   
Aminoacylation is a two-step process, requiring ATP (Ibba and Soll 2000), thus making it 
strongly dependent on the cellular metabolic state.  All members of the aaRS family share a 
conserved structure, with one catalytic domain and one anticodon binding domain (Suzuki 
et al. 2011). Some aaRSs have also been shown to possess proofreading ability via a 
hydrolytic domain in their catalytic core that can remove mismatched aminoacids (Pang et 
al. 2014).  
 
Mitochondrial aaRSs have been intensely studied and recently a number of laboratories have 
associated mutations in aaRSs to mitochondrial diseases. The clinical presentation of the 
affected patients is broad, with mutations in different aaRSs affecting different systems or 
organs (Sissler et al. 2017). For example, mutations in histidyl-tRNA synthetase (HARS2), 
or in leucyl-tRNA synthetase (LARS2) can lead to Perrault’s syndrome, with sensorineural 
hearing loss and ovarian dysgenesis (Demain et al. 2017), while mutations in aspartyl-tRNA 
synthetase (DARS2) lead to a leukoencephalopathy with cerebellar ataxia and cognitive 
impairment (Uluc et al. 2008; van Berge et al. 2014), and mutations in alanyl-tRNA 
synthetase (AARS2) give rise to cerebellar ataxia, hypertrophic cardiomyopathy and delayed 
motor development (Götz et al. 2011; Mazurova et al. 2017). 
 
Mutations in the mitochondrial tryptophanyl-tRNA synthetase (WARS2) have been 
associated with an array of clinical symptoms, ranging from intellectual disability, speech 
impairment and ataxia (Musante et al. 2017), severe encephalopathy with infantile onset, 
epilepsy and spastic quadriplegia (Theisen et al. 2017), lactic acidosis, hypotonia, dystonia 
and cardiomyopathy (Wortmann et al. 2017), symptoms related to Parkinson’s disease 
(Burke et al. 2018), hypoglycaemia, and hepatotoxicity (Vantroys et al. 2018). In total, 13 
different variants have been reported in 14 subjects from 10 families. In particular, 
p.Lys313Met has been reported in six different families (Wortmann et al. 2017; Theisen et 
al. 2017; Vantroys et al. 2018; Maffezzini et al. 2019), although a common ancestry of this 
variant has not been investigated. All patients carrying the p.Lys313Met variant presented 
with white matter involvement in the central nervous system and a muscle phenotype, 
leading to muscle weakness and movement impairment, but it is still unclear what molecular 
mechanisms lie behind the pathology. 
 
Further studies are required to fully understand whether the tissue specificity in aaRSs-
related disorders is just due to different energy demands and use or whether toxicity of non-
processed intermediates could also play a role. 
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2 AIMS 
 
Next-Generation Sequencing (NGS) has revolutionized diagnostics, resulting in a large 
number of novel disease-causing genes being identified. Especially IEM, which 
predominantly are caused by monogenic alterations, have gained from NGS, with hundreds 
of genes now associated with metabolic derangements.  
The aim of the presented studies was to validate pathogenicity of newly identified gene 
variants of patients with IEM, and to identify molecular mechanisms of disease progression.  
 
The specific goals of each study are:  
Paper I to validate mutations in SQSTM1/p62 causing a slowly progressive, early onset 
neurodegeneration, and study the process of autophagy in patient cell lines.  
 
Paper II to further dissect the mechanism by which absence of SQSTM1/p62 can lead to a 
central nervous system pathology. For this, patient fibroblasts were reprogrammed to induced 
Pluripotent Stem cells (iPSCs) and further differentiated to NES cells and neurones.  
 
Paper III to validate TXNIP as a novel metabolic disease-causing gene. The bioenergetic 
and metabolic consequences were studied in patient-derived fibroblasts and myoblasts. 
 
Paper IV to validate two mutations in WARS2 as pathological and characterise their 
outcome. For this, genetically modified yeast models, as well as patient-derived NES cells 
were used. Furthermore, a Drosophila melanogaster model shed a light on the importance of 
WARS2 for life. 
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3  MATERIALS AND METHODS 
 
All of the work here presented would not have been possible without the kindness of the 
families involved. Informed consent was obtained for all involved subjects and studies were 
conducted according to the guidelines of the institute. 
3.1 Introduction to whole-genome and whole-exome sequencing 
 
In recent years, the possibility to exploit the enormous amount of information contained in 
our DNA has become close to reality thanks to NGS technology, of which Whole-Exome 
Sequencing (WES) and Whole-Genome Sequencing (WGS) are common applications. Apart 
from the obvious curiosity some of us might have in knowing the details of their own 
molecular heritage, these approaches have the captivating potential of enabling the fast 
identification of possible pathologic mutations (Stranneheim et al. 2014).  
 
The main difference between the two methods lies in the isolation procedure and in the 
amount of data they generate. WES provides researchers and clinicians with information 
only concerning the coding sequences of our genome, while WGS provides data on close to 
all our 3 billion base pairs. Technical and computational limitations had favoured WES as 
the preferred method in detecting clinically relevant variants, but recent advances in both 
sequencing and data handling has now allowed clinics to shift to WGS. Although the 
interpretation of variants in non-coding regions is in the majority of cases still difficult, 
sample preparation, downstream computational protocols, and a better coverage of potential 
splice sights, make WGS now the preferred method for clinical variant calling.  
Ever since their first applications, both WES (Choi et al. 2009; Ng et al. 2010) and WGS 
(Nordström et al. 2013) have proved reliable in identifying possible causative mutations. In 
some way, the identification of the disease-causing variant in a sea of 3 billion base pairs 
can be compared to finding the preverbal needle in the haystack, and has only been made 
possible due to advances in molecular biology, genetics, and computational sciences. For the 
scope of this thesis, it should be noted that both WES and WGS have been shown to be of 
particular importance, as they provide a fast and efficient way to identify the mostly 
monogenic metabolic disorders (Stranneheim et al. 2014).  
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3.2 Introduction to cell reprogramming 
 
The need for adequate models is a long-known issue in every field of research. Choosing the 
right one is, in fact, of invaluable significance to give the correct interpretation to the 
observed phenomena. This concern is especially amplified in the case of neuroscience and 
the study of neurodegeneration. In this case it is virtually impossible to acquire any material 
from patients, as the access to the affected tissues is impracticable in living individuals and 
neurones, being post-mitotic cells, cannot be efficiently cultured for many passages. 
The use of animal models, especially mice and rats, is today widespread, but the fact that not 
all syndromes are recapitulated in the observed species renders it complicated to design a 
satisfactory approach to the problem.  
Tumour cell lines have also been exploited, but they are quite distantly related to the central 
nervous system and its cellular components, making it difficult at times to conclude anything 
from the observed results.  
 
In 2012 the Nobel prize in Medicine was awarded to Sir John Gurdon and Shinya Yamanaka 
for the reprogramming of mature cells. According to Gurdon’s studies on frogs, 
transplanting the nucleus of a fertilised egg into an enucleated egg of the same species leads 
to full development of embryos, suggesting that there are some factors that, on their own, 
can influence and address cellular fate (Gurdon et al. 2017).  
In 2006 Takahashi and Yamanaka published their seminal paper on the generation of induced 
iPSCs from mouse embryonic and adult fibroblasts. The group identified a minimum number 
of factors required to sufficiently induce regression towards stemness, i.e. toward a state of 
pluripotency, in mature, differentiated cells. These factors were the four transcription factors 
Oct3/4, Klf4, Sox2, and c-Myc. The such gained iPSCs resembled physiological embryonic 
stem cells in morphology and expression of embryonic markers. Furthermore, they could be 
differentiated into a number of different cell types from all three germ layers (Takahashi and 
Yamanaka 2006). Nowadays, the number of factors and technology used to obtain iPSCs 
has been reduced and simplified (Löhle et al. 2012), allowing for the adaptation of 
reprogramming in a variety of scientific fields.  
The potential to differentiate iPSCs into neurones has proven to be of specific importance, 
and numerous disease models have since been reported, including models for Alzheimer’s 
(Kondo et al. 2013), Parkinson’s (Kikuchi et al. 2017), ALS (Park et al. 2016), or simply 
ageing (Mertens et al. 2018).  
In 2009, Koch and colleagues proved it possible to obtain stable neural precursor cultures 
from human embryonic stem cells, allowing the constant proliferation of neuroprogenitor 
cells. Despite their long-term maintenance of plasticity, they could, if correctly stimulated, 
give rise to specific neuronal subpopulations (Koch et al. 2009).  
In 2012, Anna Falk and her colleagues demonstrated the possibility of inducing previously 
reprogrammed iPSCs into lines of neuronal lineage (NES cells) that will show all neuronal 
precursors markers and can then be further differentiated into a mixed neuronal and glial 
population, much like what was seen with embryonic stem cells (Falk et al. 2012). With this 
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protocol, there is no need for culturing of human embryonic stem cells, which could rise 
ethical, as well as practical, issues, but neuronal precursors can be directly obtained from 
adult patients and their differentiated cell lines. 
 
In our papers, NES cells were cultured in DMEM/F12 medium containing N-2 supplement 
(1:100), B-27 supplement (1:1000), 10 ng/µL basic Fibroblast Growth Factor (bFGF) and 
10 ng/µL Epidermal Growth Factor (EGF). Removal of these factors and increase of B-27 
concentration to 1:100 resulted in induction of neuronal differentiation.  
The cells thus obtained constituted a mixed pool of neuronal subtypes and only prolonged 
culturing originated astrocytic presence.  
 
3.3 Introduction to CRISPR/Cas9 
 
Before the advent of the Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)/CRISPR-associated Protein (Cas) 9 method, Zinc Fingers Nucleases (ZFNs) and 
Transcription Activator-Like Effector Nucleases (TALENs) were the only ways to artificially 
edit a specific locus in the genome. Yet, designing the correct experiment was quite tricky 
and the need for an efficient approach became more and more urgent. 
The first discovery of CRISPR was in bacteria, where short, palindromic repeats seemed to 
be of particular importance for the immune system response (Hille and Charpentier 2016). In 
2013 it was demonstrated that directing Cas9 with guide RNAs could efficiently be 
engineered to precisely cleave DNA in human cells (Cong et al. 2013). Guiding the nuclease 
Cas9 to the DNA region of interest promotes double-strand breaks (DSBs) that can then either 
be repaired with homologous recombination, or by non-homologous end joining (NHEJ). In 
the first case, an exogenous DNA template with homologous ends can be provided, allowing 
the integration of specific sequences or point mutations into the locus of interest. In the 
second instance, NHEJ often results in the deletion of short DNA stretches, providing the 
possibility to generate knock out models for the gene of interest (Adli 2018). The simplicity 
and high efficiency of CRISPR/Cas9 technology has resulted in its use in a wide range of 
applications, from drug screening to the generation of animal models (Ma et al. 2014; Motta 
et al. 2017; Qi et al. 2017).  
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3.4 Introduction to oxygen consumption measurements 
 
Ever since the mid of the last century, the Clark electrode has been used to measure oxygen 
concentration. In this system, a silver (Ag/AgCl) anode and a platinum cathode, are covered 
by a membrane permeable to molecular oxygen. Reduction of oxygen at the cathode is 
dependent on the partial pressure of oxygen itself diffusing through the membrane, and can 
be considered a measure of oxygen concentration in the environment.  
 
A number of commercially available systems have been adapted on the principle of the Clark 
electrode, to allow to measure changes in oxygen concentration over time and therefore 
respiratory rate in mitochondria. One of the most widely used systems is the Oroboros 
oxygraph (Oroboros Instruments GmbH). In this system, samples are injected in a closed, 
isolated chamber, with the possibility to supply various substrates to differentially activate 
or inhibit complexes of the ETC. The prime derivative of oxygen decrease over time 
represents a measure of oxygen consumption and, indirectly, of mitochondrial activity. 
Analysis of the decrease in oxygen in the chamber after each step of the protocol can thus 
help to identify mitochondrial deficiencies and dysfunctions. The main advantage of this 
method lies in its flexibility, with a wide range of applications and protocols possible to cater 
for a number of research questions.  
 
Another commonly used system to evaluate mitochondrial function is the Seahorse 
(Seahorse XF Analyzers, Agilent). Although both systems are designed to evaluate 
mitochondrial oxygen consumption, the Oroboros measures respiration in cell suspension, 
while the Seahorse measures oxygen consumption in seeded cells, using fluorescent sensors 
that can measure both oxygen concentration and pH in the cell media. The main advantage 
of the Seahorse system is the automation and scalability of the system, with up to 96 samples 
measured in parallel, while the Oroboros requires manual manipulation with only two 
possible samples. 
Both systems described have been used in this thesis. 
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4 RESULTS AND DISCUSSION 
4.1 Paper I 
Paper I comprises the first description of patients with loss-of-function mutations in the 
autophagy adaptor protein SQSTM1/p62. Together, nine patients from four unrelated families 
were reported, all presenting with clear signs of central nervous system dysfunctions from the 
pre-adolescent age, suffering from gait abnormalities, ataxia, dysarthria, vertical gaze palsy, 
dystonia and cognitive decline. Clinical symptoms were slowly progressive, with the oldest 
affected patient now well above 40 years of age. Brain MRI revealed iron accumulation, 
typically associated to mitochondrial dysfunction with central nervous system involvement, in 
only one of the affected families, while cerebellar atrophy was evident in four of the subjects, 
albeit not in all. Mitochondrial function, when investigated, showed a mild decrease of 
Complex IV activity, but normal ATP production rates. WES identified three bi-allelic loss of 
function variants that led to complete absence of p62 at transcript and protein levels in the pool 
of nine patients. 
The suggested role of p62 in mitophagy, together with the mild ETC dysfunction, led us to 
investigate the mitochondrial clearance upon mitochondrial stress exposure. The protonophore 
carbonyl cyanide m-chlorophenyl hydrazone (CCCP) has previously been suggested to induce 
p62-dependent mitophagy, as it depolarises mitochondrial membrane potential and induces 
PINK1 extrusion, resulting in fragmentation of the mitochondrial network in both patient and 
control fibroblast cell lines. Although prolonged exposure to CCCP resulted in the expected 
mitochondrial clearance, patient cell lines failed to sufficiently form mitochondrial perinuclear 
aggregates upon short CCCP exposure, typically associated with mitophagy (Narendra et al. 
2010). 
Overexpression of Parkin nicely co-localised with the mitochondrial network, but did not revert 
the observed phenotype, in agreement with the hypothesis of p62 being dispensable for disposal 
of damaged mitochondria by Parkin.  Treating the cells with a combination of oligomycin 
(inhibitor of ATP synthase) and antimycin A (inhibitor of Complex III of the ETC) did not 
reveal any obvious defect in patient cells regarding autophagosome formation or mitochondrial 
clearance. 
This manuscript described the first patients deficient of the p62 protein, presenting with a 
slowly-progressive neurodegeneration. Studies of autophagy in the fibroblasts of these patients 
highlight a defect in perinuclear translocation of mitochondria upon depolarisation, but no 
further impairment in clearance of defective organelles, suggesting not only a dispensable 
activity of p62 in the processes mediated by Parkin, but also hinting at a composite redundancy 
in the activity of different participants in the pathway. 
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4.2 Paper II 
 
In Paper II I further investigate the molecular mechanisms underlying the clinical progression 
in two patients with homozygous null mutations in p62 (the two siblings presenting with the 
c.286C>T, p.Arg96* mutation) (Haack et al. 2016). The strictly neurological presentation led 
us to generate NES cells from both patients, as well as SQSTM1 knock out NES cells by 
CRISPR/Cas9 gene editing technology. Differentiation potential of NES cells was severely 
reduced in patient cell lines, which was accompanied by the reduced expression of several 
neuronal lineage markers. This phenotype was confirmed both in CRISPR/Cas9 p62 knock out 
cells, silencing of p62 by RNAi in control NES cells, and could be rescued by reintroducing 
full-length p62 into patient NES cells, which resulted in improved differentiation and long-
range projection formation. 
 
In agreement with observations made in patient fibroblasts, NES cells lacking p62 presented 
with reduced Complex I and IV activities, but normal ATP production, and had normal 
mitochondrial clearance in response to mitochondrial damage. However, NES cells lacking 
p62 presented with increased sensitivity to both CCCP and 2, 4-dinitrophenol (DNP), an 
additional protonophore, suggesting increased sensitivity to oxidative stress. The fluorescent 
dye CM-H2DCFDA, which is an indicator for ROS and thus for oxidative stress, did not show 
any difference in basal ROS levels between control and patient NES cells. However, increased 
ROS levels could be observed upon induction of differentiation, accompanied by decreased 
expression of genes involved in the glutathione system. This phenotype could be partially 
reverted by treatment with the antioxidant N-Acetyl Cysteine (NAC). The expression of 
KEAP1 and several other factors involved in ROS management were not changed in patient 
cells, suggesting a possible role of SQSTM1 in the oxidative stress response, independent from 
the KEAP1-Nrf2-ARE pathway.  
Transcriptomic and proteomic analysis on CRISPR/Cas9 knock out, patient and control cells 
revealed impaired up-regulation of aerobic metabolism pathways upon neuronal differentiation 
induction. Neuronal differentiation requires the cells to undergo a metabolic shift from a 
glycolytic metabolism to a more aerobic profile. Zheng and colleagues previously 
demonstrated that reduction of lactate dehydrogenase A (LDHA) was essential for this process 
during neuronal differentiation (Zheng et al. 2016). Indeed, NES cells lacking p62 presented 
with an altered pyruvate metabolism, including a severe increase in LDHA expression, both on 
transcript and protein level. Surprisingly, though, fibroblasts from patients lacking p62 did not 
show increased LDHA expression. 
 Cell culture is usually performed at atmospheric oxygen concentrations, while oxygen pressure 
in the brain is much lower. The increased sensitivity to oxidative stress suggested a defect in 
oxygen sensing. We therefore chose to expose NES cells to 3% oxygen, a more physiologically 
relevant oxygen concentration, and could observe a defect in the dynamic response of the 
hypoxia inducible factor 1-alpha (Hif-1a).  
  21 
In conclusion, we show that neuronal precursors lacking p62 exhibit a defect in maturation. 
This limitation is not caused by impairment in mitochondrial clearance, but due to the inability 
to activate their metabolic profile to a more aerobic energy metabolism, possibly because of 
increased sensitivity to oxidative stress and increased LDHA levels.  
4.3 Paper III 
In Paper III I present three siblings with mutations in the TXNIP gene. WES analysis 
identified two homozygous nucleotide variants close to each other (c.174G>T, p.Gln58His and 
c.175G>T, p.Gly59*), leading to no detectable TXNIP expression. The subjects presented with 
lactic acidosis and low serum methionine levels. Evidence of hypoglycemia, liver involvement, 
and muscle weakness were also noted but not in all three siblings. Diagnostic investigation of 
mitochondrial function on muscle biopsies failed to identify a defect in mitochondrial 
respiration or isolated respiratory chain enzyme activities. 
As previously mentioned, TXNIP is an oxidative stress mediator by inhibiting thioredoxin 
activity. However, patient cell lines presented with normal thioredoxin activity in myoblasts 
from all three patients. In contrast, in agreement with previous reports, loss of TXNIP resulted 
in a robust up-regulation of the entire Nrf2 system.  
Investigations in patient cell lines revealed increased lactate release into the extracellular 
medium, indicating a pronounced use of anaerobic energy pathways.  This was confirmed when 
cells were treated with the Complex V inhibitor oligomycin. Measuring cellular respiration on 
intact patient cells, using a Seahorse analyzer, revealed a severe defect in mitochondrial 
respiration, when providing pyruvate as the sole carbon source. In contrast, supplementation 
with malate, an additional carbon source entering the respiratory chain at Complex I, showed 
normal mitochondrial respiration, suggesting a severe defect in pyruvate metabolism in the 
absence of TXNIP. Interestingly though, pyruvate dehydrogenase activity, the complex 
decarboxylating pyruvate to acetyl-CoA, which enters the TCA cycle, was normal in patient 
samples, suggesting either impaired pyruvate import into the cell, or into mitochondria. 
In conclusion, I report the first patients with non-sense mutations in TXNIP, resulting in lactic 
acidosis and reduced serum methionine levels. Further, the results suggest an important role of 
TXNIP in regulating the use of pyruvate for aerobic energy metabolism. Failure to further 
oxidise pyruvate during aerobic metabolism leads to the observed lactate accumulation.  
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4.4 Paper IV 
In Paper IV I report two pathogenic variants in the mitochondrial tryptophanyl-tRNA 
synthetase (WARS2) gene. Two siblings carrying the c.938A>T, p.Lys313Met and c.833T>G, 
p.Val278Gly compound heterozygous variants presented with a severe neurological syndrome, 
muscle weakness, hypotonia, ataxia, and developmental delay. The Lys313Met variant has 
previously been reported by Theisen et al. 2017, Wortmann et al. 2017 and Vantroys et al. 
2018, while the Val278Gly variant has not been described previously. 
To evaluate the pathogenicity of our mutations, the variants were modelled in yeast. 
Neither variant is conserved in yeast and therefore the equivalent yeast amino acids were 
mutated into both the human control, as well as patient amino acids. Humanisation of the 
p.Val278 (p.I297V in yeast) showed normal growth under non-fermentable growth conditions, 
with normal respiration at both 28°C and 37°C growth conditions. In contrast, the patient-
specific variant (p.I297G in yeast) resulted in a failure to grow in non-fermentable conditions, 
and a severe respiratory rate defect. In contrast, humanisation, as well as introduction of the 
patient p.Lys313Met (p.E333M in yeast) variant, had no effect on growth on glycerol, nor 
affected the respiratory rate at 28°C. However, shifting growth to 37°C revealed a reduced 
respiratory rate, for both humanised and patient mutation, suggesting that any alteration at this 
position can result in a biochemical defect. 
Neither the diagnostic investigation of fresh muscle biopsies, nor measurements of respiratory 
rate and isolated respiratory chain enzyme activities in patient fibroblasts, revealed a 
mitochondrial dysfunction in either patient, although an aminoacylation defect of 
mitochondrial tRNATrp could be observed by Northern blot analysis. In contrast, NES cells, 
derived from reprogrammed patient fibroblasts did present with a mild Complex I and IV 
defect. Finally, in an attempt to mimic the reduced aminoacylation of mitochondrial tRNATrp, 
WARS2 was silenced by RNAi in a Drosophila melanogaster animal model. Full-body knock 
down of Dm-wars2 resulted in reduced aminoacylation of tRNATrp , triggering larval lethality 
and reduced mitochondrial respiration. Together, this manuscript provides molecular and 
biochemical evidence from three different model systems that the observed variants in WARS2 
indeed could be the case for the clinical symptoms observed in the patients. 
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5 CONCLUSIONS 
 
Metabolism is a complex, intricate network of processes that sustains all cellular activities and 
ultimately life. This system is not infallible: problems and imbalances can always occur and 
lead to clinically relevant situations. The chances of solving peculiar cases and gaining insight 
into the genetic causes of multiple clinically relevant situations have in the last years escalated, 
thanks to the design of WES and WGS protocols.  
In particular, mitochondria are protagonists of aerobic energy metabolism and in the past years 
have been connected with complex clinical presentations including neurodegeneration and 
ageing.  
In Paper I and paper II I explore the aetiology of an early-onset, slowly-progressive 
neurodegenerative syndrome related to loss of the autophagy adaptor protein SQSTM1/p62. 
The results of this study demonstrate how important the ability to efficiently balance different 
metabolic pathways is to proper neuronal development.  
In Paper III, I analyse the case of three siblings with loss of TXNIP. This study supports the 
idea that the ROS balance is also essential for metabolism and cellular well-being.  
Lastly, in Paper IV I explore another neurodegenerative syndrome that affects two siblings 
presenting with mutations in the WARS2 gene, highlighting the importance of using the correct 
model for validation of novel disease variants. 
Summing up, the studies collected here unveil a number of apparently unrelated pathological 
mechanisms, all bound to metabolism and energy management. 
The impact rare disorders have is sometimes underestimated: the work here presented tries to 
highlight their possible implications into more common and widespread disorders. 
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